Will Kidney Disease Patients Finally Receive New Drug Class? Will Kidney Disease Patients Finally Receive New Drug Class?
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 19, 2023 Category: Consumer Health News Tags: Nephrology News Source Type: news
NICE draft advice backs further treatment option for heart failure patients
NICE has issued final draft guidance recommending empagliflozin as an option for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. (Source: GP Online News)
Source: GP Online News - October 5, 2023 Category: Primary Care Tags: NICE Guidelines Source Type: news
Drug Makers Agree to Negotiate With Medicare on Prices of 10 Medications
President Biden at the White House on Monday. The first negotiations will be over 10 drugs selected by the administration, including blood thinners Eliquis and Xarelto and the diabetes drugs Jardiance and Januvia. The pharmaceutical companies said they would begin talks even as several of them…#xarelto #medicare #karinejeanpierre #maryland #democrats #republicans (Source: Reuters: Health)
Source: Reuters: Health - October 3, 2023 Category: Consumer Health News Source Type: news
Drugmakers opt in to Medicare drug price negotiations
A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020. All drugmakers of the first 10 medicines selected for Medicare drug price negotiations have agreed to participate in the talks, even after many of them sued to halt the…#eliquis #provo #utah #medicare #jardiance #boehringeringelheim #xarelto #januvia #farxiga #enbrel (Source: Reuters: Health)
Source: Reuters: Health - October 2, 2023 Category: Consumer Health News Source Type: news
Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK ’s Drugs
This week, the European Commission granted marketing approval to AbbVie’s ABBV Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA approved Lilly’s LLY diabetes drug, Jardiance (empagliflozin), for expanded use in chronic kidney disease…#europeancommission #abbvies #fda #lilly #lly #sanofi #dupixent #merck #pah #jnj (Source: Reuters: Health)
Source: Reuters: Health - September 30, 2023 Category: Consumer Health News Source Type: news
Empagliflozin Gets FDA Nod for CKD Without T2D or HF Empagliflozin Gets FDA Nod for CKD Without T2D or HF
The US Food and Drug Administration gave the SGLT2 inhibitor empagliflozin (Jardiance) a new indication for treating adults with isolated chronic kidney disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 27, 2023 Category: Cardiology Tags: Nephrology News Alert Source Type: news
US FDA Approves Jardiance for the Treatment of Adults with Chronic Kidney Disease
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 22, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Approves Another SGLT2 Inhibitor for Treating CKD
(MedPage Today) -- The SGLT2 inhibitor empagliflozin (Jardiance) nabbed a new indication for the treatment of adults with chronic kidney disease (CKD) regardless of diabetes status, Boehringer Ingelheim and Eli Lilly announced.
Data from the phase... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 22, 2023 Category: Cardiology Source Type: news
Biden targets diabetes drug Jardiance, blood thinner Eliquis and 8 others for Medicare price talks
President Joe Biden says for many Americans the cost of one drug can be “the difference between life and death” as his administration announces the first drugs that’ll be targeted for price negotiations in an effort to cut Medicare costs (Source: ABC News: Health)
Source: ABC News: Health - August 29, 2023 Category: Consumer Health News Tags: Health Source Type: news
The 10 Drugs Medicare Can Negotiate Were Just Announced. These Pharma Stocks Are Impacted
Eliquis, Jardiance, and Stelara are among the first of 10 different drugs that are now subject to Medicare price negotiations following the passing of the Inflation Reduction Act.#medicare (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2023 Category: Consumer Health News Source Type: news
Biden targets diabetes drug Jardiance, blood thinner Eliquis and 8 others for Medicare price talks
By TOM MURPHY, AMANDA SEITZ and CHRIS MEGERIAN | Associated Press WASHINGTON — The blood thinner Eliquis and popular diabetes treatments including Jardiance are among the first drugs that will be targeted for price negotiations in an effort to cut Medicare costs. President Joe Biden’s…#tommurphy #amanda #chris #eliquis #medicare #joebidens #merck #amgen #entresto #novartis (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2023 Category: Consumer Health News Source Type: news
Here Are the First 10 Drugs Biden Will Target for Price Negotiations
WASHINGTON (AP) — The popular diabetes treatment Jardiance and the blood thinner Eliquis are among the first drugs that will be targeted for price negotiations in effort to cut Medicare costs.
President Joe Biden’s administration on Tuesday released a list of 10 drugs for which the federal government will take a first-ever step: negotiating drug prices directly with the manufacturer.
[time-brightcove not-tgx=”true”]
The move is expected to cut costs for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers. It’s also a centerpiece of t...
Source: TIME: Health - August 29, 2023 Category: Consumer Health News Authors: TOM MURPHY, AMANDA SEITZ and CHRIS MEGERIAN / AP Tags: Uncategorized wire Source Type: news
Eliquis and Jardiance Among First Drugs Picked for Medicare Price Negotiations
The Biden administration ’s announcement was an important moment for Democrats, who have campaigned on a promise to lower the cost of prescription drugs. (Source: NYT)
Source: NYT - August 29, 2023 Category: American Health Authors: Sheryl Gay Stolberg and Rebecca Robbins Tags: Drugs (Pharmaceuticals) Medicare Inflation Reduction Act of 2022 Biden, Joseph R Jr Health and Human Services Department Health Insurance and Managed Care Prices (Fares, Fees and Rates) Democratic Party United States Politics and Governmen Source Type: news
Stocks trending in afternoon trading: Beyond Meat, Eli Lilly, and Palantir
Corporate results were driving big moves in a variety of stocks on Tuesday afternoon, while a positive development on Novo Nordisk's (NVO) Wegovy weight-loss drug sent big pharma stocks soaring. Below is a breakdown of some of the biggest movers on Yahoo Finance's trending tickers page. Eli Lilly…#novonordisk #nvo #yahoofinance #elililly #lly #davidricks #mounjaro #jardiance #anatashkenazi #beyondmeat (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2023 Category: Consumer Health News Source Type: news
Europe Approves Empagliflozin for Chronic Kidney Disease Europe Approves Empagliflozin for Chronic Kidney Disease
The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - July 27, 2023 Category: Internal Medicine Tags: Diabetes & Endocrinology News Alert Source Type: news
